I hate to be that guy, but it's apoptosis, with an extra "p".
As to insurance providers, he's speaking about health insurers in the US already anticipating FDA approval for Ryoncil and Revascor (as evidenced by documents they have produced, noting when the treatment is applicable).
This indicates at least THEIR expectation that those treatments may be approved for their respective diseases in the near term. I would argue it is NOT material and need not be reported to the market, but does indicate a much higher level of industry awareness for the treatments, their current stage of review in the approval process, and to a slight degree, their sense that it's reasonably likely they will be approved. Very positive, but NOT market moving and not price sensitive.
Just another "tick" for those of us that read every single tea leaf to try to discern where things are at.
- Forums
- ASX - By Stock
- Countdown to Interim Analysis
I hate to be that guy, but it's apoptosis, with an extra "p". As...
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.20 |
Change
-0.105(8.05%) |
Mkt cap ! $1.364B |
Open | High | Low | Value | Volume |
$1.27 | $1.30 | $1.17 | $12.26M | 9.967M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 38602 | $1.20 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.20 | 31698 | 14 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 9584 | 1.190 |
17 | 68131 | 1.185 |
17 | 166852 | 1.180 |
11 | 79698 | 1.175 |
12 | 97362 | 1.170 |
Price($) | Vol. | No. |
---|---|---|
1.195 | 55236 | 14 |
1.200 | 50287 | 18 |
1.205 | 119045 | 14 |
1.210 | 57297 | 9 |
1.215 | 38425 | 4 |
Last trade - 12.11pm 24/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
Previous Video
Next Video
SPONSORED BY The Market Online